Challenge for an “Allergy-Free World”
HISHOH Biopharma's novel immunostimulant will maximize the potential of allergen immunotherapy and realize an allergy-free world.
HSO-001 synergistically lowered antibody levels, a measure of efficacy against hay fever. Based on these results, HSO-001 is expected to produce faster and longer-lasting effects.
AIT is considered the only effective curative therapy for IgE-mediated type I allergic diseases such as allergic rhinitis, asthma, and atopic dermatitis.
- We issued our new website.
- Sublingual immunotherapy was introduced on the LINK-J website.
- Nikkei Biotech published an article about our company
- Execution of a license agreement for a substance with immunostimulatory properties and implementation of a third-party allocation of new shares in the seed round
Founder and CEO
Naoki Sakurai, Ph.D.
Naoki Sakurai joined HISHOH Biopharma in May, 2021. He has a demonstrated executive history and an extensive R&D background in the pharmaceutical industry with over 30 years of managerial experience in both Japan and the USA. Previously he served as President & CEO of Tanabe Research Laboratories USA where he progressed multiple biologics projects into clinical and preclinical stages. Before that, he worked with Mitsubishi Tanabe Pharma responsible for diverse research functions as well as in-licensing and open-innovation alliances with external organizations.
Dr. Sakurai received his B.S., M.S., and Ph.D. from Kyoto University.
Graduated from Kyoto University (B.A., M.A., Ph.D.); joined the Company in May 2021
Michihito Onishi built a strong experience of science, R&D and business as a researcher and business development personnel in Taisho Pharmaceutical for 18 years. Since 2016, he successfully supported many licensing deals between biotech companies in the West and Japanese pharmaceutical companies at Locust Walk Japan, transaction advisory firm, and Ora, Inc., an ophthalmic company. He joined HISHOH Biopharma from the establishment and play a lead role for business development. He obtained his master degree from Kobe university and M.B.A. from Kenichi Ohmae Graduate School of Business.
Co-founder and Advisor
After earning a PhD from Wake Forest University School of Medicine in the United States, Toru Seo engaged in education as an associate professor of pediatrics at Columbia University School of Medicine. Since 2006, he has been engaged in R & D and business development at GSK, Merck, and Taisho Pharmaceutical. Since 2015, he has been the General Manager of Japan for External Science & Innovation and the General Manager of Asia for Worldwide Research & Development at Pfizer Inc. In addition, while being involved in venture company support and ecosystem construction as an angel investor and parallel entrepreneur, he also works as a consultant and bio-venture advisor for domestic and overseas companies.
BioLite Japan K.K.
Mitsubishi UFJ Capital Co.
DBJ Capital Corporation
Daiichi Sankyo Company, Limited